Product Information
GUANFACINE HCL ER 4 MG TABLET is a generic product labeled by Slate Run Pharmaceuticals LLC, priced at $0.1762 per EA under NDC 70436004201. Its NADAC has been published 204 times since Nov 9, 2022.
FDA first approved this application on Nov 25, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 mg/1
Manufacturer
Slate Run Pharmaceuticals LLCNDC
70436004201
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GUANFACINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA213428FDA Approved
11/25/2020
TE Code
AB
On Market Since
8/1/2022
Pharmacological Classes
Price Statistics
The NADAC for GUANFACINE HCL ER 4 MG TABLET has been published 204 times since Nov 9, 2022, and over the history we have for it it has declined 28.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1762 per EA |
|---|---|
| All-time high | $0.2844 (Dec 13, 2023) |
| All-time low | $0.1661 (Nov 20, 2024) |
| 52-week high | $0.2118 |
| 52-week low | $0.1681 |
| Median price | $0.2043 |
| Average price | $0.2127 |
| Largest weekly change | +27.1% (Nov 22, 2023) |
| Weeks tracked | 204 |
| Tracking since | Nov 9, 2022 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Slate Run Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
guanfacine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central alpha-2 Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GUANFACINE HCL ER 4 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GUANFACINE HCL ER 4 MG TABLET, manufactured by Slate Run Pharmaceuticals LLC, is $0.1762 per EA (NDC 70436004201), effective Sep 30, 2026.
How has the price of GUANFACINE HCL ER 4 MG TABLET changed over time?
Over the history we have for it, the NADAC for GUANFACINE HCL ER 4 MG TABLET has declined 28.1%. It has been tracked across 204 weekly CMS publications since Nov 9, 2022.
What are the highest and lowest recorded NADAC prices for GUANFACINE HCL ER 4 MG TABLET?
Since Nov 9, 2022, the NADAC for GUANFACINE HCL ER 4 MG TABLET has ranged from a low of $0.1661 (Nov 20, 2024) to a high of $0.2844 (Dec 13, 2023), with a median of $0.2043 per EA.
Are there cheaper alternatives to GUANFACINE HCL ER 4 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GUANFACINE HCL ER 4 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures GUANFACINE HCL ER 4 MG TABLET?
GUANFACINE HCL ER 4 MG TABLET (NDC 70436004201) is labeled by Slate Run Pharmaceuticals LLC, and CMS classifies it as a generic product.